Immunotherapies enhance patients’ endogenous immune system function of attacking tumor cells, and are being widely and successfully used in the field of immuno-oncology.
New therapeutic classes and combinations are changing the cancer landscape, bringing the promise of significant patient benefits. But they can complicate trial and commercialization strategies.
pharmaphorum media and Symplur, LLC launch Conference360 Report to help pharma and other stakeholders understand social media conversations around medical congresses
The rising cost of oncology drugs has been drawing increasing questions from payers, providers and regulators about the relative value of individual therapies and how to quantify that value in ligh